How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

1,018 results for

Dyspepsia in Pregnancy

by
...
Latest & greatest
Alerts

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

61. Step-up and step-down treatment strategies did not differ for symptom relief at 6 months in new onset dyspepsia

patients ⩾18 years of age (54% women) who visited their general practitioner for new onset dyspepsia (pain or discomfort in upper abdomen and originating in upper gastrointestinal tract). Exclusion criteria included gastroscopy in the past year, use of prescribed acid suppressive medication in the past 3 months, alarm symptoms (dysphagia, weight loss, anaemia, or haematemesis), pregnancy, or insufficient knowledge of Dutch. Intervention: step-up treatment (n = 341) given in 3 four-week steps: (1 (...) Step-up and step-down treatment strategies did not differ for symptom relief at 6 months in new onset dyspepsia Step-up and step-down treatment strategies did not differ for symptom relief at 6 months in new onset dyspepsiaCommentary | BMJ Evidence-Based Medicine We use cookies to improve our service and to tailor our content and advertising to you. You can manage your cookie settings via your browser at any time. To learn more about how we use cookies, please see our . Log in using your

2009 Evidence-Based Medicine

62. Peptic ulceration in pregnancy: report of a case with perforation. (Full text)

Peptic ulceration in pregnancy: report of a case with perforation. 5929536 1966 07 14 2018 11 13 0008-4409 94 16 1966 Apr 16 Canadian Medical Association journal Can Med Assoc J Peptic ulceration in pregnancy: report of a case with perforation. 861-2 Baird R M RM eng Case Reports Journal Article Canada Can Med Assoc J 0414110 0008-4409 AIM IM Adult Dyspepsia Female Gastrectomy Humans Peptic Ulcer Perforation Pregnancy Pregnancy Complications 1966 4 16 1966 4 16 0 1 1966 4 16 0 0 ppublish

1966 Canadian Medical Association Journal PubMed abstract

63. Obstetrics in General Practice: Minor Disorders of Pregnancy (Full text)

Obstetrics in General Practice: Minor Disorders of Pregnancy 14102023 1996 12 01 2018 12 01 0007-1447 1 5385 1964 Mar 21 British medical journal Br Med J OBSTETRICS IN GENERAL PRACTICE. MINOR DISORDERS OF PREGNANCY. 749-52 PHILIPP E E EE eng Journal Article England Br Med J 0372673 0007-1447 OM Anemia Anxiety Back Pain Classification Constipation Dyspepsia Family Practice Female General Practice Heartburn Hemorrhoids Hernia, Diaphragmatic Humans Hypertension Migraine Disorders Muscle Cramp (...) Obstetrics Paresthesia Pre-Eclampsia Pregnancy Pregnancy Complications Sleep Wake Disorders Trichomonas Vaginitis Urinary Tract Infections Urination Disorders Varicose Veins Vomiting ANEMIA ANXIETY BACKACHE CLASSIFICATION CONSTIPATION DIAPHRAGMATIC HERNIA DYSPEPSIA GENERAL PRACTICE HEARTBURN HEMORRHOIDS HYPERTENSION MIGRAINE MUSCLE CRAMP PARESTHESIA PREGNANCY PREGNANCY COMPLICATIONS PREGNANCY TOXEMIAS SLEEP DISORDERS TRICHOMONAS VAGINITIS URINARY TRACT INFECTIONS URINATION DISORDERS VARICOSE VEINS

1964 British medical journal PubMed abstract

64. BRAVO Study for Functional Dyspepsia

BRAVO Study for Functional Dyspepsia BRAVO Study for Functional Dyspepsia - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one or more studies before adding more. BRAVO Study for Functional Dyspepsia (BD) The safety and scientific validity (...) : Background: Functional dyspepsia is one of the commonest digestive disorders. The pathophysiology of functional dyspepsia is uncertain. Proton pump inhibitor (PPI) has been recommended as the first line treatment for functional dyspepsia. However, the results on effectiveness of PPI are conflicting and it has been suggested that PPI is only effective for acid-related symptoms. The investigators plan to use a wireless pH monitoring system positioned at the junction of esophagus and stomach to evaluate

2011 Clinical Trials

65. Efficacy and Safety of Cinitapride Tablets in the Treatment of Mild to Moderate Functional Dyspepsia

Efficacy and Safety of Cinitapride Tablets in the Treatment of Mild to Moderate Functional Dyspepsia Efficacy and Safety of Cinitapride Tablets in the Treatment of Mild to Moderate Functional Dyspepsia - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please (...) remove one or more studies before adding more. Efficacy and Safety of Cinitapride Tablets in the Treatment of Mild to Moderate Functional Dyspepsia The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our for details. ClinicalTrials.gov Identifier: NCT01355276 Recruitment Status : Completed First Posted : May 18, 2011 Last Update Posted : November 30, 2011

2011 Clinical Trials

66. Corticotropin Releasing Hormone (CRH) Responsiveness in Children With Functional Dyspepsia

; Scheduled for endoscopy to evaluate dyspepsia following non-response to standard acid reduction therapy; >20kg/45 lbs. and, Group 2 (Controls): Ages 8-17 inclusive; >20kg/45 lbs. Exclusion Criteria: Both groups: Previous abdominal surgery; <20 kg/45 lbs.: Pregnancy; Chronic disease requiring regular medical care (e.g. diabetes mellitus, juvenile rheumatoid arthritis, cystic fibrosis, cancer); or, Non-English speaking. Controls: Recent history (within 6 months) of abdominal pain, nausea, vomiting (...) Corticotropin Releasing Hormone (CRH) Responsiveness in Children With Functional Dyspepsia Corticotropin Releasing Hormone (CRH) Responsiveness in Children With Functional Dyspepsia - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one or more

2011 Clinical Trials

67. The Clinical Significance of Acid Rebound in Functional Dyspepsia

The Clinical Significance of Acid Rebound in Functional Dyspepsia The Clinical Significance of Acid Rebound in Functional Dyspepsia - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one or more studies before adding more. The Clinical Significance (...) of Acid Rebound in Functional Dyspepsia (CLARIFY) The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our for details. ClinicalTrials.gov Identifier: NCT01373970 Recruitment Status : Terminated First Posted : June 15, 2011 Last Update Posted : December 6, 2013 Sponsor: Zealand University Hospital Information provided by (Responsible Party): Anders Bergh

2011 Clinical Trials

68. Plasma Levels of Glucagon-like Peptide-2 and Dyspepsia in Patients With Extraintestinal Cancer During Chemotherapy

Plasma Levels of Glucagon-like Peptide-2 and Dyspepsia in Patients With Extraintestinal Cancer During Chemotherapy Plasma Levels of Glucagon-like Peptide-2 and Dyspepsia in Patients With Extraintestinal Cancer During Chemotherapy - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number (...) of saved studies (100). Please remove one or more studies before adding more. Plasma Levels of Glucagon-like Peptide-2 and Dyspepsia in Patients With Extraintestinal Cancer During Chemotherapy The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our for details. ClinicalTrials.gov Identifier: NCT01382667 Recruitment Status : Completed First Posted : June 27

2011 Clinical Trials

69. Use of Maytenus Ilicifolia in the Treatment of Dyspepsia

, Older Adult) Sexes Eligible for Study: All Accepts Healthy Volunteers: No Criteria Inclusion Criteria: age > 18 years being literate diagnosis of dyspepsia initial SODA score > or = 25 Exclusion Criteria: pregnancy lactation allergy to Maytenus species fail to use the drug for 3 uninterrupted weeks new onset serious adverse events, attributable to the drug patient's request Contacts and Locations Go to Information from the National Library of Medicine To learn more about this study, you or your (...) Use of Maytenus Ilicifolia in the Treatment of Dyspepsia Use of Maytenus Ilicifolia in the Treatment of Dyspepsia - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one or more studies before adding more. Use of Maytenus Ilicifolia in the Treatment

2011 Clinical Trials

70. IQoro for hiatus hernia

or long courses of medication. Current NHS pathway or current care pathway NICE's guideline on gastro-oesophageal reflux disease and dyspepsia in adults: investigation and management recommends offering a full-dose proton pump inhibitor (PPI) long-term as maintenance treatment for people with severe oesophagitis (reflux disease). Laparoscopic fundoplication should be considered for people who have a confirmed diagnosis of acid reflux and enough symptom control with acid suppression therapy but who do (...) for NICE's guideline on gastro- oesophageal reflux disease and dyspepsia in adults, published in 2014. IQoro may be resource releasing compared with long-term PPI maintenance. It also has a cheaper up-front cost than laparoscopic fundoplication. IQoro for hiatus hernia (MIB176) © NICE 2019. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and- conditions#notice-of-rights). Page 3 of 12Resource consequences According to the company, there are around 10,000 users

2019 National Institute for Health and Clinical Excellence - Advice

71. Tigecycline

classes. Concurrent use of antibiotics with oral contraceptives may render oral contraceptives less effective. Based on an in vitro study tigecycline is a P-gp substrate. Co-administration of P-gp inhibitors (e.g., ketoconazole or cyclosporine) or P-gp inducers (e.g., rifampicin) could affect the pharmacokinetics of tigecycline (see section 5.2). 4.6 Fertility, pregnancy and lactation Pregnancy There are no or limited amount of data from the use of tigecycline in pregnant women. Studies in animals (...) you closely. Tigecycline Accord may interfere with the contraceptive pill (birth control pill). Talk to your doctor about the need for an additional method of contraception while receiving Tigecycline Accord. Pregnancy and breast-feeding Tigecycline Accord may cause foetal harm. If you are pregnant or breast-feeding, think you may be pregnant or are planning to have a baby, ask your doctor for advice before taking this medicine. It is not known if tigecycline passes into breast milk in humans. Ask

2020 European Medicines Agency - EPARs

72. Cerebral palsy in under 25s: assessment and management

://www.nice.org.uk/terms-and- conditions#notice-of-rights). Page 3 of 461 Optimising nutritional status in children with cerebral palsy 44 2 Managing communication difficulties in children with cerebral palsy 44 3 Recognition and early management of pain in children and young people with cerebral palsy 45 4 Association between treating infections in pregnancy and rates of cerebral palsy 45 5 Prevalence of mental health problems in young people (up to the age of 25) with cerebral palsy 46 Cerebral palsy in under (...) of pain, discomfort and distress identified in children and young people with cerebral palsy, treat the cause as appropriate using targeted interventions in line with the following NICE guidelines: spasticity in under 19s constipation in children and young people gastro-oesophageal reflux disease in children and young people and gastro- oesophageal reflux disease and dyspepsia in adults headaches in over 12s low back pain and sciatica in over 16s urinary incontinence in neurological disease urinary

2017 National Institute for Health and Clinical Excellence - Clinical Guidelines

73. Management of Dyslipidaemias (Full text)

and secondary prevention 43 9.3.2 Adverse effects, interactions, and adherence 43 9.4 Diabetes and metabolic syndrome 43 9.4.1 Specific features of dyslipidaemia in insulin resistance and type 2 diabetes 43 9.4.2 Evidence for lipid-lowering therapy 44 9.4.2.1 Low-density lipoprotein cholesterol 44 9.4.2.1 Triglycerides and high-density lipoprotein cholesterol 44 9.4.3 Type 1 diabetes 45 9.4.4 Management of dyslipidaemia for pregnant women with diabetes 45 9.5 Patients with acute coronary syndromes

2019 European Society of Cardiology PubMed abstract

74. Clostridioides difficile Infection in Adults and Children

. difficile Infection in Patients =18 Years of Age Disease Severity Initial Episode 1 First Recurrence 1 Second Recurrence 1 Mild-Moderate (Disease is considered Mild-Moderate when the criteria for severe or fulminant disease are not met) Metronidazole 7.5 mg/kg/dose PO QID for 10 days 2 , maximum 500 mg/dose OR Patients with metronidazole allergy, pregnant, nursing, on warfarin therapy, or who fail to improve after 3-5 days of PO metronidazole: Vancomycin 10 mg/kg/dose PO QID, up to maximum 125 mg PO QID (...) Management Strategy for CDI Table 5. Guidance on Preemptive Isolation for Patients with Diarrhea Preemptive isolation should be considered if patients have diarrhea (3 or more watery stools in 12 to 24 hours) * not caused by laxative use, chemotherapy, enteral feeds or other medical causes AND AT LEAST ONE of the following: ? Current or prior antibiotic use (within 30 days) ? Significant abdominal pain, not caused by incisional pain, dyspepsia, or nausea ? History of C. difficile ? Suspect C. difficile

2020 University of Michigan Health System

75. Iron Deficiency – Diagnosis and Management

history, symptom review and physical examination. Directed history should include: nutrition and physical activity history pregnancy status and number of pregnancies history of blood loss, including GI bleeding, hematuria, menorrhagia, and blood donation GI symptoms including changes in bowel habits, abdominal pain, dyspepsia, and unexplained weight loss family history including colorectal cancer Menorrhagia is the most frequent cause of iron deficiency among pre-menopausal women. Consider referral (...) for guidance. If hemoglobin is correcting by 4 weeks, continue oral iron and check CBC and ferritin at three months. Iron Deficiency and Obstetrics There is an increase in iron requirement (about 1000 mg total) during pregnancy, parturition and lactation. , Iron is essential for normal fetal development. It is important to prevent iron deficiency in the fetus by preventing iron deficiency in pregnant women. Assess risk of iron deficiency among women planning pregnancy, especially women in high-risk groups

2019 Clinical Practice Guidelines and Protocols in British Columbia

76. Trastuzumab (Ogivri) - breast cancer or stomach cancer

predictive of human response, trastuzumab should be avoided during pregnancy unless the potential benefit for the mother outweighs the potential risk to the foetus. In the post-marketing setting, cases of foetal renal growth and/or function impairment in association with oligohydramnios, some associated with fatal pulmonary hypoplasia of the foetus, have been reported in pregnant women receiving trastuzumab. Women who become pregnant should be advised of the possibility of harm to the foetus (...) . Pharmacokinetic data from Study H4613g/GO01305 suggested that carboplatin had no impact on the PK of trastuzumab. The administration of concomitant anastrozole did not appear to influence the pharmacokinetics of trastuzumab. 4.6 Fertility, pregnancy and lactation Women of childbearing potential Women of childbearing potential should be advised to use effective contraception during treatment with trastuzumab and for 7 months after treatment has concluded (see section 5.2). Pregnancy Reproduction studies have

2019 European Medicines Agency - EPARs

77. Istradefylline (Nourianz) - Parkinson's disease

belonging to narrow SMQs with incidence of at least 1% greater than placebo for Pool 1. The only TEAEs related to laboratory analysis belonged narrow SMQ with incidence of at least 1% greater than placebo was Hyperglycaemia/New Onset Diabetes Mellitus. The following table shows the incidence by dose. Overall, the maximum difference from placebo was low at = 65 13.7 7.4 Fall, dizziness, balance disorder = 65 8.2 9.8 Dyspepsia, N, V, indigestion, epigastric pain, gastritis, duodenitis = 65 5.4 5.6 (...) Insomnia, sleep disturbance, abnormal dreams = 65 3.9 3.3 Nausea, vomiting = 65 4.1 3.7 Abdominal pain, distension, bloating, spasm, IBS = 65 6.2 6 Reviewer created table from the ISS ADAE dataset with ANL01FL=Y, studyID=6002-US-005, 6002-0608, 6002-009, 6002-US-013. Grouped by USUBJID, AEDECOD, and TRPO1A. *Denominator: All IST = 75 8.6 7.3 Fall, dizziness, balance disorder = 75 12.9 12.7 Dyspepsia, N, V, indigestion, epigastric pain, = 75 6.5 14.5 Insomnia, sleep disturbance, abnormal dreams = 75 4.3

2019 FDA - Drug Approval Package

79. Abdominal and pelvic imaging

choice for initial evaluation of several intra-abdominal conditions, especially in the right upper quadrant and in the pelvis and especially in pediatric patients and pregnant women. Computed tomography (CT) is often utilized for imaging the abdomen and pelvis. It provides excellent 3- dimensional resolution and can be performed relatively quickly, reducing the potential for motion artifact. A major drawback of CT is the dose of ionizing radiation required for image acquisition, which (...) is of particular concern in younger patients and those who require multiple scans over time. CT may be performed with or without contrast; contrast provides additional detail to delineate vascular and gastrointestinal structures and is recommended in certain settings, such as infection, tumor, hemorrhage and visceral lesions. However, contrast increases scan acquisition time, and confers risk in cases of impaired renal function, pregnancy, metformin use, radioactive iodine treatment for thyroid disease

2020 AIM Specialty Health

80. Assessment of nausea and vomiting, adults

dysrhythmias Gastroparesis Bacterial peritonitis Anorexia nervosa Bulimia nervosa Pregnancy Drug-induced Nephrolithiasis Uraemia Idiopathic functional dyspepsia or post-prandial distress syndrome Acute coronary syndrome Postural orthostatic tachycardia syndrome (POTS) Meniere's disease Acoustic neuroma Traumatic brain injury Meningitis Brain abscess Complex partial seizures CNS tumours Primary adrenal insufficiency (acute or chronic) Hyperthyroidism Hypopituitarism Heat stroke Acute pancreatitis Bariatric

2018 BMJ Best Practice

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>